SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 2170797

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 2170797

Latent Tuberculosis Infection Detection Market - Global Forecast 2026-2032

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (1-5 Users License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 5959

Add to Cart

The Latent Tuberculosis Infection Detection Market is projected to grow by USD 2.31 billion at a CAGR of 6.49% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.48 billion
Estimated Year [2026] USD 1.58 billion
Forecast Year [2032] USD 2.31 billion
CAGR (%) 6.49%

Latent Tuberculosis Infection Detection: Executive Overview

Latent tuberculosis infection (LTBI) detection identifies people infected with Mycobacterium tuberculosis who do not have active tuberculosis disease. The principal tools are tuberculin skin testing (TST) and interferon-gamma release assays (IGRAs), supported by clinical assessment and evaluation for active disease when indicated. Detection is central to tuberculosis prevention because treatment of appropriately identified LTBI can reduce progression to active disease, particularly among people with recent exposure or elevated clinical risk.

Screening Is Shifting Toward Risk-Based, Targeted Detection

The landscape is moving from broad, low-yield screening toward targeted testing of people with documented exposure, recent migration from high-transmission settings, immunosuppression, healthcare or congregate-setting exposure, and other recognized risk factors. IGRAs are increasingly used where BCG vaccination may reduce the specificity of TST, while TST remains important where laboratory infrastructure, cost, or workforce capacity constrain blood-based testing. Better linkage between testing, confirmatory evaluation, and preventive treatment is becoming as important as the initial test choice.

Artificial Intelligence Can Strengthen Workflow Without Replacing Diagnosis

Artificial intelligence can support LTBI programs by prioritizing people for screening, identifying missed follow-up, improving interpretation of radiographic findings used to exclude active disease, and helping health systems allocate testing capacity. Its value depends on representative training data, transparent validation, privacy safeguards, and integration with clinical workflows. AI cannot by itself establish LTBI, and algorithmic outputs require qualified clinical review alongside microbiological, radiological, and epidemiological evidence.

Regional Priorities Reflect Differences in Transmission and Health-System Capacity

North America generally emphasizes targeted screening among contacts, immigrants from high-burden settings, people receiving immunosuppressive therapies, and selected occupational groups. Latin America combines household-contact investigation with efforts to improve access to testing and preventive treatment. Europe faces varied epidemiology across countries and continues to prioritize migrants, contacts, and vulnerable populations. The Middle East and Africa require stronger integration of contact investigation, HIV and immunosuppression services, and primary care. Asia-Pacific contains both high-burden settings and advanced low-incidence programs, making decentralized access, quality assurance, and risk-based screening especially important.

Multilateral Groups Can Align Standards, Procurement, and Follow-Up

ASEAN members can benefit from interoperable approaches to contact tracing, migrant health, and laboratory quality across diverse health systems. BRICS countries have an opportunity to coordinate research, diagnostics access, and implementation experience across large and varied populations. The European Union can reinforce common guidance, cross-border continuity of care, and surveillance interoperability. G7 members can support evidence generation, laboratory strengthening, and equitable access. GCC countries can focus on screening and continuity of care for mobile workforces and migrants, while NATO members can strengthen preparedness and standardized approaches for military and operational populations.

Country Contexts Require Tailored Detection Pathways

Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States generally rely on risk-based strategies supported by contact investigations, immigrant and refugee health services, and screening before selected immunosuppressive treatments. Brazil, India, China, Indonesia, Mexico, Russia, and South Korea must balance substantial tuberculosis-control needs with differing laboratory access, BCG practices, and regional variation. Japan combines mature public-health infrastructure with targeted screening of contacts and clinically vulnerable groups. Across all listed countries, the most effective pathway connects a positive TST or IGRA with timely exclusion of active disease, preventive-treatment decisions, adherence support, and outcome monitoring.

Industry Leaders Should Connect Testing With Complete Care Pathways

Leaders should prioritize accurate, accessible tests and design services around the full cascade of care rather than test volume alone. This includes clear risk-based eligibility criteria, dependable specimen transport, internal quality controls, rapid result communication, clinical decision support, and referral pathways for preventive treatment. Partnerships with public-health programs can improve contact investigation and reach underserved populations. Organizations should also measure invalid or indeterminate results, time to clinical evaluation, preventive-treatment initiation and completion, equity of access, and safety outcomes. Digital tools and AI should be deployed only with governance, human oversight, and evidence of performance in the populations served.

Methodology: Evidence-Based Synthesis of Detection Practice

This executive summary synthesizes established clinical and public-health principles for LTBI detection, including the roles of TST and IGRA, risk-based screening, exclusion of active tuberculosis, contact investigation, and preventive-treatment linkage. The geographic analysis uses the requested regional, group, and country lenses to describe implementation priorities without assigning numerical market values. Conclusions are framed around documented epidemiological and health-system differences, while avoiding unsupported estimates, forecasts, company attribution, or market-share claims.

Effective LTBI Detection Depends on Integration and Equity

LTBI detection is most effective when testing is targeted to meaningful risk, interpreted in clinical context, and connected rapidly to active-disease evaluation and preventive treatment. Regional and country differences make a single operational model unsuitable, but common priorities remain: reliable diagnostics, trained staff, equitable access, high-quality data, and sustained follow-up. Artificial intelligence may improve coordination and prioritization, yet responsible implementation requires validation and clinical accountability. The strongest programs will treat detection as one component of an integrated tuberculosis-prevention pathway.

Product Code: MRR-1CF12C86008C

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Latent Tuberculosis Infection Detection Market, by Test Type

  • 7.1. Introduction
  • 7.2. Tuberculin Skin Test (TST)
  • 7.3. Interferon-Gamma Release Assays (IGRAs)
    • 7.3.1. T-SPOT.TB
    • 7.3.2. QuantiFERON-TB Gold (QFT)

8. Latent Tuberculosis Infection Detection Market, by Offering

  • 8.1. Introduction
  • 8.2. Software & Services
  • 8.3. Reagents & Consumables
  • 8.4. Instruments
  • 8.5. Assays & Kits

9. Latent Tuberculosis Infection Detection Market, by Application

  • 9.1. Introduction
  • 9.2. People Living with HIV
  • 9.3. Household Contacts with Pulmonary TB

10. Latent Tuberculosis Infection Detection Market, by End User

  • 10.1. Introduction
  • 10.2. Public Health Agencies & Government Bodies
  • 10.3. Hospitals
  • 10.4. Diagnostic Laboratories
  • 10.5. Clinics
  • 10.6. Academic & Research Institutions

11. Latent Tuberculosis Infection Detection Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. Europe
  • 11.4. North America
  • 11.5. Latin America
  • 11.6. Africa
  • 11.7. Middle East

12. Latent Tuberculosis Infection Detection Market, by Group

  • 12.1. Introduction
  • 12.2. NATO
  • 12.3. G7
  • 12.4. BRICS
  • 12.5. European Union
  • 12.6. ASEAN
  • 12.7. GCC

13. Latent Tuberculosis Infection Detection Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. China
  • 13.4. Germany
  • 13.5. Japan
  • 13.6. India
  • 13.7. United Kingdom
  • 13.8. France
  • 13.9. Canada
  • 13.10. Australia
  • 13.11. Brazil
  • 13.12. Italy
  • 13.13. Mexico
  • 13.14. South Korea
  • 13.15. Russia
  • 13.16. Spain

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. AID Autoimmun Diagnostika GmbH
  • 15.3. ARKRAY, Inc.
  • 15.4. Becton, Dickinson and Company (BD)
  • 15.5. Beijing Wantai Biopharmaceutical Co., Ltd.
  • 15.6. Bio-Rad Laboratories, Inc.
  • 15.7. bioMerieux S.A.
  • 15.8. Bioneovan Co., Ltd.
  • 15.9. Biopanda Reagents Ltd.
  • 15.10. Boditech Med Inc.
  • 15.11. InBios International, Inc.
  • 15.12. Liofilchem S.r.l.
  • 15.13. Lionex GmbH
  • 15.14. Mylab Discovery Solutions Pvt. Ltd.
  • 15.15. Omega Diagnostics Group PLC
  • 15.16. QIAGEN N.V.
  • 15.17. Revvity, Inc.
  • 15.18. Sanofi S.A.
  • 15.19. SD Biosensor, Inc.
  • 15.20. Serum Institute of India Pvt. Ltd
  • 15.21. Thermo Fisher Scientific Inc.

16. Key Experts

Product Code: MRR-1CF12C86008C

LIST OF FIGURES

  • FIGURE 1. Global Latent Tuberculosis Infection Detection Market, Years Considered for the Study
  • FIGURE 2. Global Latent Tuberculosis Infection Detection Market, Research Design
  • FIGURE 3. Global Latent Tuberculosis Infection Detection Market, Research Framework
  • FIGURE 4. Global Latent Tuberculosis Infection Detection Market, Data Triangulation
  • FIGURE 5. Global Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Latent Tuberculosis Infection Detection Market Size, by Test Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Latent Tuberculosis Infection Detection Market Size, by Test Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Latent Tuberculosis Infection Detection Market Size, by Offering, 2025 vs 2032 (%)
  • FIGURE 9. Global Latent Tuberculosis Infection Detection Market Size, by Offering, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Latent Tuberculosis Infection Detection Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 11. Global Latent Tuberculosis Infection Detection Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Latent Tuberculosis Infection Detection Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 13. Global Latent Tuberculosis Infection Detection Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Latent Tuberculosis Infection Detection Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global Latent Tuberculosis Infection Detection Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Latent Tuberculosis Infection Detection Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Latent Tuberculosis Infection Detection Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global Latent Tuberculosis Infection Detection Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Latent Tuberculosis Infection Detection Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Latent Tuberculosis Infection Detection Market Segmentation & Coverage
  • TABLE 2. Global Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 4. Global Tuberculin Skin Test (TST) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Tuberculin Skin Test (TST) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Tuberculin Skin Test (TST) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Interferon-Gamma Release Assays (IGRAs) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Interferon-Gamma Release Assays (IGRAs) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Interferon-Gamma Release Assays (IGRAs) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global T-SPOT.TB Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global T-SPOT.TB Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global T-SPOT.TB Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global QuantiFERON-TB Gold (QFT) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global QuantiFERON-TB Gold (QFT) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global QuantiFERON-TB Gold (QFT) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 17. Global Software & Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Software & Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Software & Services Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Reagents & Consumables Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Reagents & Consumables Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Reagents & Consumables Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Instruments Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Instruments Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Instruments Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Assays & Kits Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Assays & Kits Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Assays & Kits Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 30. Global People Living with HIV Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global People Living with HIV Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global People Living with HIV Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Household Contacts with Pulmonary TB Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Household Contacts with Pulmonary TB Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Household Contacts with Pulmonary TB Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 37. Global Public Health Agencies & Government Bodies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Public Health Agencies & Government Bodies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Public Health Agencies & Government Bodies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Academic & Research Institutions Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Academic & Research Institutions Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Academic & Research Institutions Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Asia-Pacific Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Asia-Pacific Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 55. Asia-Pacific Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 56. Asia-Pacific Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 57. Asia-Pacific Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 58. Asia-Pacific Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 59. Europe Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Europe Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 61. Europe Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 62. Europe Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 63. Europe Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 64. Europe Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 65. North America Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. North America Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 67. North America Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 68. North America Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 69. North America Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 70. North America Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 71. Latin America Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Latin America Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 73. Latin America Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 74. Latin America Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 75. Latin America Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 76. Latin America Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 77. Africa Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Africa Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 79. Africa Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 80. Africa Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 81. Africa Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 82. Africa Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 83. Middle East Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Middle East Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 85. Middle East Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 86. Middle East Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 87. Middle East Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 88. Middle East Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 89. Global Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 90. NATO Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. NATO Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 92. NATO Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 93. NATO Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 94. NATO Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 95. NATO Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 96. G7 Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 97. G7 Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 98. G7 Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 99. G7 Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 100. G7 Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 101. G7 Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 102. BRICS Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. BRICS Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 104. BRICS Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 105. BRICS Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 106. BRICS Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 107. BRICS Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 108. European Union Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 109. European Union Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 110. European Union Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 111. European Union Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 112. European Union Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 113. European Union Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 114. ASEAN Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 115. ASEAN Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 116. ASEAN Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 117. ASEAN Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 118. ASEAN Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 119. ASEAN Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 120. GCC Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 121. GCC Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 122. GCC Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 123. GCC Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 124. GCC Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 125. GCC Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 126. Global Latent Tuberculosis Infection Detection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 127. United States Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 128. United States Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 129. United States Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 130. United States Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 131. United States Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 132. United States Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 133. China Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 134. China Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 135. China Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 136. China Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 137. China Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 138. China Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 139. Germany Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 140. Germany Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 141. Germany Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 142. Germany Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 143. Germany Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 144. Germany Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 145. Japan Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 146. Japan Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 147. Japan Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 148. Japan Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 149. Japan Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 150. Japan Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 151. India Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 152. India Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 153. India Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 154. India Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 155. India Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 156. India Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 157. United Kingdom Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 158. United Kingdom Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 159. United Kingdom Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 160. United Kingdom Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 161. United Kingdom Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 162. United Kingdom Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 163. France Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 164. France Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 165. France Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 166. France Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 167. France Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 168. France Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 169. Canada Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 170. Canada Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 171. Canada Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 172. Canada Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 173. Canada Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 174. Canada Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 175. Australia Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 176. Australia Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 177. Australia Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 178. Australia Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 179. Australia Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 180. Australia Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 181. Brazil Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 182. Brazil Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 183. Brazil Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 184. Brazil Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 185. Brazil Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 186. Brazil Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 187. Italy Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 188. Italy Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 189. Italy Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 190. Italy Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 191. Italy Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 192. Italy Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 193. Mexico Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 194. Mexico Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 195. Mexico Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 196. Mexico Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 197. Mexico Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 198. Mexico Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 199. South Korea Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 200. South Korea Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 201. South Korea Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 202. South Korea Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 203. South Korea Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 204. South Korea Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 205. Russia Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 206. Russia Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 207. Russia Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 208. Russia Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 209. Russia Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 210. Russia Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 211. Spain Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 212. Spain Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 213. Spain Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 214. Spain Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 215. Spain Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 216. Spain Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 217. Global Latent Tuberculosis Infection Detection Market Share, by Key Player, 2025
  • TABLE 218. Global Latent Tuberculosis Infection Detection Market, Key Experts
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!